Skip to main content

Search

Important Medicine Safety Information

Important Medicine Safety Information
Jun 20, 2024

Recommended Calculations Of Contraception Duration After Completion Of Therapy To Minimise The Risk Of Embryotoxicity And Teratogenicity Associated With The Use Of Genotoxic Anticancer Medicines (Including Potential Metabolites)

The risk of acute tubulointerstitial nephritis (TIN) associated with proton pump inhibitors (PPIs)

GOLIMUMAB SIMPONI 50 MG: IMPORTANT CHANGES TO THE INSTRUCTIONS FOR USE (IFU) FOR THE SMARTJECT AUTOINJECTOR/PRE-FILLED PEN 

IMBRUVICA (IBRUTINIB) – RISK OF FATAL CARDIAC EVENTS

COVID-19 VACCINES JANSSEN: RISK OF IMMUNE THROBOCYTOPENIA (ITP) AND VENOUS THROMBOEMBOLISM (VTE)

COVID-19 VACCINE JANSSEN: CONTRADICTION IN INDIVIDUALS WITH PREVIOUS CAPILLARY LEAK SYNDROME (CLS) & RISK OF THROMBOSIS IN COMBINATION WITH THROMBOCYTOPENIA

COVID-19 VACCINE JANSSEN: RISK OF THROMBOSIS IN COMBINATION WITH THROMBOCYTOPENIA

Warning about cerebro-vascular events, cerebro-vascular accident, cerebral infraction, ischaemic stroke and transcient ischaemic attack associated with the use of tyrosine kinase inhibitor containing medicines